Transcription of HIGHLIGHTS OF PRESCRIBING INFORMATION …
{{id}} {{{paragraph}}}
Example: bankruptcy
HIGHLIGHTS OF PRESCRIBING INFORMATION …
HIGHLIGHTS OF PRESCRIBING INFORMATION metastatic gastric or gastroesophageal junction adenocarcinoma These HIGHLIGHTS do not include all the INFORMATION needed to use whose tumors express PD-L1 [Combined Positive Score (CPS). KEYTRUDA safely and effectively. See full PRESCRIBING 1] as determined by an FDA-approved test, with disease INFORMATION for KEYTRUDA. progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if KEYTRUDA (pembrolizumab) for injection, for intravenous use appropriate, HER2/neu-targeted ( ). KEYTRUDA (pembrolizumab) injection, for intravenous use Cervical Cancer Initial Approval: 2014 for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose ---------------------------RECENT MAJOR CHANGES --------------------------- tumors express PD-L1 (CPS 1) as determined by an FDA- Indications and Usage (1) 06/2018 approved ( ).
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEYTRUDAsafely and effectively. See full prescribing
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: